Cetuximab with radiotherapy in patients with loco-regionally advanced squamous cell carcinoma of head and neck unsuitable or ineligible for concurrent platinum-based chemo-radiotherapy: Ready for routine clinical practice?
Cetuximab with radiotherapy in patients with loco-regionally advanced squamous cell carcinoma of head and neck unsuitable or ineligible for concurrent platinum-based chemo-radiotherapy: Ready for routine clinical practice?
复制标题
DOI：
10.4103/0019-509x.82872
复制
发表时间：
2011-04-01
影响因子：
1
通讯作者：
D'cruz, A. K.
中科院分区：
文献类型：
--
作者：
Agarwal, J. P.;Gupta, T.;D'cruz, A. K.
目的：报告西妥昔单抗联合放疗治疗不适合铂类放化疗的晚期头颈癌的结果。材料和方法：对在综合癌症中心接受西妥昔单抗和放射治疗的 37 名患者进行回顾性图表审查。结果：研究队列的中位年龄为 59 岁。三十四名 (92%) 患者患有晚期疾病（III-IV 期）。不符合铂类治疗资格的原因包括肌酐清除率受损、年老和/或合并症。三十二名（86%）患者不间断地完成了计划的放疗； 29 名 (80%) 患者接受了≥ 6 个周期的西妥昔单抗治疗。 15 名患者 (40.5%) 出现 >= 3 级皮炎； 9 名患者 (25%) 经历过≥ 3 级粘膜炎。中位随访 16 个月时，2 年局部区域控制率、无病生存率和总生存率分别为 35.5%、29.5% 和 44.4%。分期分组和严重皮炎是结果的重要预测因素。结论：西妥昔单抗联合放疗是晚期头颈癌患者的合理替代方案，其依从性和结果可接受，但皮肤毒性较高。
PURPOSE: To report outcomes of cetuximab concurrent with radiotherapy in advanced head-neck cancer unsuitable for platinum-based chemo-radiotherapy. MATERIALS AND METHODS: Retrospective chart review of 37 patients treated with cetuximab and radiotherapy at a comprehensive cancer centre. RESULTS: Median age of study cohort was 59 years. Thirty four (92%) patients had advanced stage disease (stage III-IV). Reasons for ineligibility for platinum included impaired creatinine-clearance, old age, and/or co-morbidities. Thirty-two (86%) patients completed planned radiotherapy without interruption; 29 (80%) patients received >= 6 cycles of cetuximab. Fifteen patients (40.5%) developed >= grade 3 dermatitis; 9 patients (25%) experienced >= grade 3 mucositis. At a median follow-up of 16 months, the 2-year loco-regional control, disease-free survival, and overall survival was 35.5%, 29.5%, and 44.4% respectively. Stage grouping and severe dermatitis were significant predictors of outcome. CONCLUSIONS: Cetuximab concurrent with radiotherapy is a reasonable alternative in advanced head-neck cancer patients with acceptable compliance and outcomes, but higher skin toxicity.